Lykke M. Ørnbjerg

Apr 1, 2024 | jrheum.org | Lykke M. Ørnbjerg |Kathrine Rugbjerg |Stylianos Georgiadis |Simon Rasmussen

RESULTSPatients. We included data on 12,262 biologic-naïve patients with PsA starting treatment with a first TNFi in a real-world setting between January 1, 2009, and December 31, 2018. Among these patients, 4329 patients later initiated a second TNFi and 1240 patients a third TNFi. Considering the first TNFi treatment course, etanercept was the most frequently prescribed drug (35% of patients), followed by adalimumab (30%), infliximab (17%), golimumab (13%), and certolizumab pegol (7%).

Feb 9, 2024 | jrheum.org | Lykke M. Ørnbjerg |Kathrine Rugbjerg |Stylianos Georgiadis |Simon Rasmussen

Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care Lykke M. Ørnbjerg, Kathrine Rugbjerg, Stylianos Georgiadis, Simon H. Rasmussen, Lennart Jacobsson, Anne G. Loft, Florenzo Iannone, Karen M. Fagerli, Jiri Vencovsky, Maria J.